Hanmi Pharmaceutical is aiming to claim the top position in the local hypertension combination treatment market with its Amosartan lineup, backed by differentiated data and a wide lineup.
Amosartan lineup consists of Amosartan, Amosartan Q, and Amosartan Plus.
Amosartan is a drug that combines the CCB (Calcium Channel Blockers)-based Amlodipine camsylate and the Angiotensin II Receptor Blocker (ARB)-based Losartan potassium, while Amosartan Plus is the world’s first drug to combine Chlorthalidone, a diuretic, and Amosartan into a single pill for a more active blood pressure level.
Amosartan Q, which improves medication compliance in patients with hypertension and hyperlipidemia, added Amosartan to Rosuvastatin, a dyslipidemia treatment, and has proven a powerful effect in reducing low-density lipoprotein cholesterol (LDL-C).
The company’s goal comes after the firm attained the number one spot in the total hypertension market last year.
The company, which has a total of 15 hypertension treatment products, including the Amosartan lineup, recorded 153 billion won ($135 million) in sales last year, a 14 percent increase from 2018. Amosartan lineup’s sales accounted for 8.3 percent of the total market sized at 1.8 trillion won, the largest share taken by a single lineup.
The lineup’s growth also has greatly contributed to winning the hypertension treatment market’s top market share.
According to Ubist, a drug market research firm, all three drugs enjoyed strong growth, with Amosartan recording 74.1 billion won sales last year, up 10 percent from 2018. Amosartan Plus recorded 18.2 billion won sales, up 84 percent, and Amosartan Q registered sales of 5.8 billion won, a hefty 164 percent increase.
Hanmi’s hypertension combination drug continued to show strong growth this year.
Although Boehringer Ingelheim’s Twynsta continued to hold the top spot in the local hypertension combination market in the first half of this year with an outpatient prescription of about 46.7 billion won, Hanmi Pharmaceutical’s Amosartan lineup growth pushed out Novartis’ Exforge and took second place with a sale of about 40.8 billion won.
The company shows high expectations for the continued growth of the product and plans to take the number one position in the local hypertension combination market.
“Amosartan has been the No. 1 outpatient prescription product among locally developed ethical drugs over the past 11 years,” a company official said. “The cumulative prescription amount of the Amosartan family totals 870 million tablets, and the number of patients taking it annually reaches 336,000.”
The cumulative prescriptions have also approached 760 billion won since the firm launched Amosartan in 2009, and the amount contributed to easing the financial burdens of the National Health Insurance Service by substituting imports worth about 183 billion won, the company said.
Hanmi noted that it had secured differentiated evidence of the treatment’s efficacy by publishing the drug’s trial results in 11 local and international SCI(Science Citation Index)-level journals.
“Our ‘K-Central Study’ clinical trial and its sub-analysis trials in 2019 was published in representative hypertension conference journals in the U.S. (American Journal of Hypertension) and Europe (Journal of Hypertension), proving the drug’s excellent efficacy in the global market,” the company said.
The K-Central Study and its sub-analysis are representative clinical trials of Amosartan. The trials showed that the treatment improved various hemodynamic indicators by evaluating the effect of controlling blood pressure in the clinic and factors that cannot be easily measured.
Hanmi stresses that it is continuing to improve the Amosartan lineup by applying the firm’s formulation technology.
“Ever since the product’s launch, we have continued to make efforts to increase the product value of Amosartan by, for instance, reducing the size of the formulation through continuous research and development and laser printing for grain identification, the first eco-friendly method used in Korea,” the company said.
Hanmi has applied for the approval of a new four combination drug as part of the Amosartan lineup for the first time in Korea.
“Hanmi will do its best to release the fourth drug soon, improving both the Amosartan lineup and widening their use in the clinical field,” it said.